Skip to main content

AMIA’s goal is to improve the legislative and regulatory environment for health informatics research, practice and education through AMIA member expertise.  The primary pathway through which AMIA achieves this goal is by engaging Federal Agencies and Congress on public calls for input, such as Notices of Proposed Rulemakings (NPRMs) or Request for Information (RFIs).

Learn more about the comment process

AMIA responses are arranged by Federal Agency and Congressional Committee.

Showing 41 - 50 out of 90

AMIA Supports Year 2 Quality Payment Program Proposals

August 21, 2017

Today, AMIA responded to a CMS Proposed Rule on Year 2 of the Quality Payment Program. AMIA supported many of the new flexibilities offer to eligible clinicians to participate in MIPS or advanced alternative payment models. The organization also urged CMS to require 2015 Edition CEHRT beginning in 2019.
 

AMIA Supports ONC Draft Framework to Measure Use of Interoperability Standards

July 25, 2017

AMIA submitted comments supporting ONC’s draft framework, recommending a measurement approach that focuses on the clinician and patient experience. AMIA also underscored the need to have the benefits of measurement outweigh the costs, and urged federal officials to provide sufficient support to develop and implement automated measurement solutions.

AMIA Supports Federal Health IT Research & Development Framework

July 12, 2017

In comments submitted to the Networking and Information Technology Research and Development (NITRD) Program, the nation’s leading biomedical and health informaticians applauded federal officials for developing a draft strategic framework for health IT research and development (R&D). AMIA provided a series of recommendations highlighting the need for R&D related to […]

AMIA Applauds Flexibilities, Supports 2015 CEHRT Timeline in IPPS Proposed Rule

June 13, 2017

In comments to CMS, AMIA supported proposals to reduce the number of required quality measures and new proposed reporting period flexibilities, while also recommending additional such flexibilities for the 2018 Hospital IQR Program and the Medicare and Medicaid EHR Incentive Programs. AMIA additionally agreed with the proposed rule’s analysis that […]

AMIA Comments Regarding FDA’s Medical Device User Fee Agreement Letter (MDUFA IV)

November 2, 2016

In comments submitted to the FDA, AMIA voiced supported for several aspects of MDUFA IV meant to enhance use of consensus standards; develop patient engagement strategies and improve the science of patient input; utilize real world evidence (RWE) to improve regulatory decision-making; and development of a policy framework for Digital […]

AMIA Response to FDA Draft Guidance on the Use of Public Human Genetic Variant Databases to Support Clinical Validity for Next Generation Sequencing (NGS)-Based In Vitro Diagnostics

October 6, 2016

In comments submitted to the FDA, AMIA said it supports FDA’s efforts to develop modern, flexible and adaptive regulatory approaches to the oversight of NGS-based tests as part of the Precision Medicine Initiative (PMI).  This support notwithstanding, AMIA noted a lack of standards – for ontologies, metadata and other technical […]

AMIA Comments Regarding FDA PDUFA VI Commitment Letter

August 16, 2016

In conjunction with a public meeting held by the FDA August 15, 2016, AMIA submitted public comments supporting the direction of the its Prescription Drug User Fee Agreement Commitment Letter.  Specifically, AMIA supports FDA’s work to utilize Real World Evidence in regulatory decision-making, incorporating the patient’s voice in drug development […]

AMIA Response to CMS Quality Payment Program NPRM

June 27, 2016

On June 27, 2016 AMIA submitted comments to CMS regarding proposed policies related to the new Medicare Quality Payments Program, which replaces the Sustainable Growth Rate and reforms how nearly 1.3 million clinicians are paid through Medicare.  AMIA described a set of principles and recommendations CMS should consider during implementation […]